Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
18 hedge funds and large institutions have $17.9M invested in Achilles Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $18.7M → $17.9M (-$780K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$60K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$20.1K |
| 3 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
+$3.23K |
| 4 |
CAS
Coppell Advisory Solutions
Coppell,
Texas
|
+$951 |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$69 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EdenTree Asset Management
London,
United Kingdom
|
-$94.5K |
| 2 |
Morgan Stanley
New York
|
-$21.6K |
| 3 |
Millennium Management
New York
|
-$21K |
| 4 |
VF
Virtu Financial
New York
|
-$16K |
| 5 |
Renaissance Technologies
New York
|
-$11.6K |
ACHL Hedge Fund Activity: Q3 2023 in Review
18 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q3 2023, worth a combined $17.9M — down 4.2% from $18.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ACHL positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Bank of America, adding an estimated $60K. The largest seller was EdenTree Asset Management, exiting entirely with an estimated $94.5K sold.
- 18 institutional investors held Achilles Therapeutics (ACHL) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $17.9M of Achilles Therapeutics stock for Q3 2023, down 4.2% quarter-over-quarter.
- 3 funds opened new Achilles Therapeutics positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest Achilles Therapeutics buyer in Q3 2023 was Bank of America, an estimated $60K added.
- The largest Achilles Therapeutics seller in Q3 2023 was EdenTree Asset Management, an estimated $94.5K sold.
Based on aggregated 13F filings for Q3 2023.